default author photo

Stefan Willmann

Bayer AG

Leverkusen

Germany

SCHOLARLY PAPERS

1

DOWNLOADS

120

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Rivaroxaban for Treatment of Paediatric Venous Thromboembolism. An EINSTEIN-Jr Phase 3 Dose-Exposure-Response Evaluation

Number of pages: 36 Posted: 26 Nov 2019
University of Southern California - Division of Infectious Diseases, Bayer AG, University of Melbourne - Department of Paediatrics, Medical University of Vienna - Department of Paediatrics, Bayer AG, Bayer AG, Cincinnati Children's Hospital Medical Center, Nationwide Children’s Hospital, Kazan Medical University - Pediatric Hospital, Indiana University - Riley Hospital for Children, Universite Paris Descartes, Noah's Ark Children's Hospital for Wales, University of Groningen - Department of Hematology and Oncology, Cook Children's Medical Center, McMaster Children's Hospital, Tel Aviv University - Sackler Faculty of Medicine, Charité - Universitätsmedizin Berlin - Department of Paediatric Oncology and Haematology, Hospital Vall d’Hebron, Université Montpellier I, Dresden University of Technology - University Hospital, A. Bianchi Bonomi Hemophilia and Thrombosis Center, University of Alberta - Department of Pediatrics, Bayer US, LLC., Bayer US, LLC., University of Florida, Dalhousie University, University Hospital Maastricht, Bayer AG and Independent
Downloads 120 (600,462)

Abstract:

Loading...

anticoagulation; bodyweight-adjusted dosing; paediatric patients; rivaroxaban; suspension; pharmacokinetics; venous thromboembolism